

Table S1. Demographics of patients with wild-type (wt) and mutant (mut) *TP53*.

		Wt (n = 306)	Mut (n = 296)	P value
Median age		57 (19-92)	61 (22-87)	.001
Female		161 (52.6)	189 (63.9)	.005
Race	Asian	51 (16.7)	64 (21.6)	.008
	Black	10 (3.3)	15 (5.1)	
	Hispanic	59 (19.3)	34 (11.5)	
	White	170 (55.6)	177 (59.8)	
	Others	16 (5.2)	6 (2.0)	
PS	0-1	261 (85.3)	261 (88.2)	.44
	2-4	33 (10.8)	23 (7.8)	
	Unknown	12 (3.9)	13 (4.0)	
CCI		1 (0-9)	1 (0-9)	.77
Treatment	Yes	241 (78.8)	233 (78.7)	.93
	No	65 (21.2)	63 (21.3)	
Histology	LMS	41 (23.6)	133 (76.4)	< .001
	UPS	55 (40.4)	81 (59.6)	
	LPS	66 (84.6)	12 (15.4)	
	Others	144 (67.3)	70 (32.7)	
<i>CDKN2A</i>	wt	199 (65.0)	264 (89.2)	< .001
	mut	107 (35.0)	32 (10.8)	
<i>RB1</i>	wt	283 (92.5)	188 (63.5)	< .001
	mut	23 (7.5)	108 (36.5)	
<i>PTEN</i>	wt	294 (96.1)	251 (84.8)	< .001
	mut	12 (3.9)	45 (15.2)	
<i>ATRX</i>	wt	211 (69.0)	169 (57.1)	< .001
	mut	14 (4.6)	53 (17.9)	
	unknown	81 (26.5)	74 (25.0)	

Note: PS, performance status; CCI, Charlson comorbidity index; LMS, leiomyosarcoma; UPS, undifferentiated pleomorphic sarcoma; LPS, liposarcoma. The number inside the parenthesis represents percent except for median age.